快速訂購

Targeted Therapy Drugs

Targeted Therapy
What is Targeted Therapy
Targeted Therapy: Targets
Targeted Therapy for Cancer
- Targeted Therapy for Kidney Cancer
- Targeted Therapy for Liver Cancer
- Colorectal Cancer Targeted Therapy
- What is Targeted Therapy for Cancer
- Targeted Therapy for Leukemia
- Targeted Therapy for Pancreatic Cancer
- Prostate Cancer Targeted Therapy
- Targeted Therapy for Ovarian Cancer
- Melanoma Targeted Therapy
- Targeted Therapy for Lung Cancer
- Targeted Therapy for Breast Cancer
EGFR Targeted Therapy
- EGFR Targeted Therapy for Breast Cancer
- EGFR Targeted Therapy for Colorectal Cancer
- EGFR Targeted Therapy for Head and Neck Cancer
- EGFR Targeted Therapy for Non-Small-Cell Lung Cancer
- EGFR Targeted Therapy for Ovarian Cancer
- EGFR Targeted Therapy for Pancreatic Cancer
HER2 Targeted Therapy
- HER2 Targeted Therapy for Breast Cancer
- HER2 Targeted Therapy for Colorectal Cancer
- Her2 targeted therapy for Ovarian cancer
VEGF Targeted Therapy
- VEGF Targeted Therapy for Breast Cancer
- VEGF Targeted Therapy for Lung Cancer
- VEGF Targeted Therapy for Prostate Cancer
- VEGF Targeted Therapy for Colorectal Cancer
BRAF Targeted Therapy
- BRAF Targeted Therapy for Melanoma
- BRAF Targeted Therapy for Lung Cancer
ALK Targeted Therapy
- ALK Targeted Therapy for Lung Cancer
- ALK Targeted Therapy for Anaplastic Large Cell Lymphoma
Immune Checkpoint Targeted Therapy
Targeted Therapy Drugs
- Targeted Therapy Drugs: Elotuzumab
- Targeted Therapy Drugs: Necitumumab
- Targeted Therapy Drugs: Daratumumab
- Targeted Therapy Drugs: Ramucirumab
- Targeted Therapy Drugs: Trastuzumab
- Targeted Therapy Drugs: Vemurafenib
- Targeted Therapy Drugs: Crizotinib
- The Differences between Chemotherapy and Targeted Therapy
Side Effects of Targeted Therapy
Oral Targeted Therapy
Targeted Therapy Resistance
How does Targeted Therapy Work
Immunotherapy
Cancer Immunotherapy
Immune checkpoint

Targeted Therapy Drugs: Introduction

The superiority of targetd therapy compared with chemotherapy make it a star in cancer therapy research. So a lot of researches have been conducted in this area. Many researches have achieved good results and steppped into clinical sections. Furthermore, some of the drugs have been approved by FDA, leading to great significances in cancer therapy.

Targeted Therapy Drugs: Elotuzumab

Elotuzumab, developed Bristol-Myers Squibb of New York, is a humanized monoclonal immunoglobulin G1 antibody targeting SLAMF7, which can be found on the surface of myeloma cells and natural killer lymphocytes in the immune system. It is approved on November 30, 2015 by the U.S. Food and Drug Administration for treating people with multiple myeloma who have received one to three prior medications in combination with two other therapies.

Targeted Therapy Drugs: Necitumumab

Necitumumab, developed by Eli Lilly, is a recombinant human IgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. It is applied in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Targeted Therapy Drugs: Daratumumab

Daratumumab, jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, by bingding to CD38 is the first monoclonal antibody approved for the treatment of multiple myeloma. It is administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.

Targeted Therapy Drugs: Ramucirumab

Ramucirumab, developed by Eli Lilly, a recombinant monoclonal antibody of the IgG1 class that binds to vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks the activation of the receptor. It is approved for the treatment of multiple sollid tumors: metastatic colorectal cancer, platinum-resistant metastatic non-small cell lung cancer, advanced gastric or gastroesophageal junction adenocarcinoma and gastric or gastroesophageal junction adenocarcinoma.

Targeted Therapy Drugs: Trastuzumab

Trastuzumab, developed by Genentech, Inc., a monoclonal antibody that interferes with the HER2/neu receptor. It is approved in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil), for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Targeted Therapy Drugs: Vemurafenib

Vemurafenib, developed by Hoffmann-La Roche Inc., a B-Raf enzyme inhibitor. It is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test.

Targeted Therapy Drugs: Crizotinib

Crizotinib, developed by Pfizer, Inc., a targted therapy drug for both ALK and ROS1. It is approved to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive in 2016. And in 2013 it is also indicated for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”